Neuropathic Pain Market Research Report Information By Type (Painful Diabetic Peripheral Neuropathy (PDPN), Autonomic Neuropathy, Focal Neuropathy, Proximal Neuropathy), By Indication (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy Induced Peripheral Neuropathy), By Diagnosis (Imaging, Blood Tests and Physical Examination), by Treatment (Medication and Multimodal Therapy), By End-user (Hospital & Clinics, Research Organization), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Global Neuropathic Pain Market Overview

Neuropathic Pain Market Size was prized at USD 2.4 billion in 2021 and is projected to grow from USD 2.6 Billion in 2022 to USD 5.2 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.7% during the forecast period (2024 - 2032). An increase in the geriatric population is predicted to increase the demand for neuropathic pain management services. The rise in diabetes and cancer prevalence, the approval of novel neuropathic pain treatment options, the proliferation of pain management clinics, and the rise in demand for neuropathic pain treatment are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

February 2024, Abbott has won FDA approval for a novel neuromodulation device intended to alleviate persistent neuropathic pain in patients. The device employs sophisticated stimulation technologies to more precisely target neural circuits.

January  2024, Sanofi has announced the launch of NeuroSan, a new neuropathic pain medicine. The medicine is intended to target specific pain circuits and is believed to have more efficacy and fewer negative effects than current treatments.

In October 2023, Anglo-French Drugs & Industries, a company based in India, unveiled the AFD-NP, a groundbreaking medicine designed to treat neuropathic pain. The combination of Nortriptyline and Pregabalin is highly recommended for the treatment of moderate to severe Neuropathic Pain. This product has been authorized by the Drug Control Department. AFD-NP consists of two chemical components, namely Nortriptyline at a dosage of 10 mg and Pregabalin at a dosage of 75 mg. Neuropathy patients experience difficulty in initiating sleep as a result of the intense agony and distress they encounter. Moreover, the discomfort is chronic, indicating that it endures for an extended duration. Nortriptyline has been shown to significantly reduce neuropathic pain and improve sleep duration. Due to its characteristic, it is quite beneficial for individuals with mild to severe neuropathy. Furthermore, when compared to gabapentin, pregabalin significantly reduces the frequency of days experiencing discomfort.

In January 2023, Abbott, a prominent multinational company, said that the FDA has approved its ProclaimTM XR spinal cord stimulation (SCS) device for the treatment of severe diabetic peripheral neuropathy (DPN), a debilitating condition caused by diabetes. Individuals suffering from diabetic peripheral neuropathy (DPN) who require alternatives to traditional treatment methods, such as oral medication, may have relief by using the Proclaim XR SCS system. Abbott's NeuroSphereTM Virtual Clinic is a connected healthcare application that enables users to remotely communicate with doctors and receive treatment adjustments. This service will be accessible to individuals who are undergoing therapy with the Proclaim XR SCS system. Abbott is committed to creating transformative solutions, such as diagnostics, nutritionals, pharmaceuticals, and medical devices like spinal cord stimulation, to enhance the quality of life for individuals with diabetes.

Neuropathic Pain Market Trends

• Rising cases of diabetics to boost the market growth

The market for treating neuropathy pain is anticipated to expand due to the increased incidence of diabetic neuropathy. The International Diabetes Federation's 2016 report, which indicated that 420 million adults had diabetes and that the number would rise by 8.4% to 625 million by 2040, is a good illustration of the rising incidence of the condition. Therefore, it is anticipated that risk factors, including smoking, being overweight or obese, and having high cholesterol levels, will increase the prevalence of diabetes, increasing the demand for neuropathic pain management devices. Thus, the rising cases of diabetics to enhanced the neuropathic pain market CAGR across the globe in recent years.

Figure 1: Estimated prevalence of diabetics in the populationSource: Secondary Research, Primary Research, MRFR Database and Analyst Review

Neuropathic Pain Market Segment Insights

Neuropathic Pain Type Insights

The neuropathic pain market segmentation is based on type, painful diabetic peripheral neuropathy (PDPN), autonomic neuropathy, focal neuropathy, and proximal neuropathy. The market growth was mainly by the peripheral segment due to an increase in peripheral neuropathy awareness on a scale. The prevalence of peripheral diabetic neuropathy in adults ranges from 6% to 51%, according to the National Center for Biotechnology Information, depending on several variables such as age, type of diabetes, glucose control, and duration of diabetes.

October 2020: Eli Lilly announced a definitive agreement to acquire Disarm Therapeutics. This privately held biotechnology company is developing a potent SARM1 inhibitor to deliver breakthrough treatments to patients suffering from peripheral neuropathy and other neurological diseases such as multiple sclerosis and amyotrophic lateral sclerosis (ALS). This agreement has further broadened the growth opportunity for the neuropathic pain industry.

The highest CAGR is anticipated for autonomic diabetic neuropathy during the projection period with respect to the neuropathic pain market revenue.A rise in demand for safe and effective therapies with few risks compared to invasive approaches is driving the sector's expansion.

Neuropathic Pain Indication Insights

The neuropathic pain market segmentation is based on indication, diabetic neuropathy, spinal stenosis, and chemotherapy-induced peripheral neuropathy. The diabetic neuropathy segment dominated the market. The rise in obesity rates due to poor food and sedentary lifestyles, as well as increased knowledge of diabetes diagnosis and treatment, are the main factors driving the diabetic neuropathy segment.

Figure 2: Neuropathic Pain Market, by Indication, 2023 & 2030 (USD Billion)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The second fastest-growing segment in the neuropathic pain industry is spinal stenosis. The growing elderly population is one of the key factors anticipated to propel the growth of spinal stenosis treatment during the forecast period.

Neuropathic Pain Diagnosis Insights

The neuropathic pain market data has been bifurcated by diagnosis imaging, blood tests and physical examination. In 2021, the imaging sector dominated the market. The need for non-invasive and minimally invasive technologies is predicted to increase, as are the therapeutic uses for brain imaging and neuroimaging equipment and the rising healthcare industry in emerging economies. However, the physical examination segment witnessed significant growth due to increased R&D spending and regulatory agencies approving neurorehabilitation devices as products.

Neuropathic Pain Treatment Insights

Based on treatment, the neuropathic pain industry has been segmented into medication and multimodal therapy. The medication segment dominates the market. Additionally, the medication sector is one of the fastest-growing market segments, expanding at a rapid CAGR due to many causes. A few drivers driving segment growth include new drug approvals resulting from extensive product development, rising demand for prescription treatments for diabetes and related problems, and a robust drug pipeline among the leading companies. Hence, rising medication applications for neuropathic pain positively impact the market growth.

Neuropathic Pain End-User Insights

The neuropathic pain market segmentation is based on end-user, hospitals & clinics, and research organizations. Physiotherapy clinics dominate the market for neuropathic pain during the anticipated timeframe. Physiotherapy has many facets, including injury prevention, health promotion, and rehabilitation. High-quality pain management equipment is necessary for the treatment. Throughout the projection period, the hospitals are anticipated to expand quickly. The use of neuropathic pain management tools is widespread in hospitals and clinics. The treatment of many types of tumors by cancer specialists makes extensive use of pain control tools.

Neuropathic Pain Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Neuropathic Pain market accounted for USD 1.06 billion in 2021 and is expected to exhibit a significant CAGR of 43.5 percent growth during the study period. This is large because of the region's growing elderly population, which causes a variety of ailments and diseases. Several initiatives from industry participants are also fueling the market's growth in the area. Vixotrigine (BIIB074) is a non-opioid experimental oral pain medication being studied to treat small fiber neuropathy. Biogen Inc. reported favorable topline data from its Phase 2 CONVEY study in September 2021, for instance (SFN).

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: NEUROPATHIC PAIN MARKET SHARE BY REGION 2023 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's neuropathic pain market accounts for the second-largest market share. The market in this region is anticipated to rise as more cancer patients choose chemotherapy, which is predicted to raise demand for pain management solutions. According to age-standardized rates, there will be 1 267 000 cancer deaths in the EU in 2021, with rates for men being 130.4/100,000 (a 6.6% decrease since 2015) and women being 81.0/100,000 (a 4.5% decrease). Further, the German neuropathic pain market held the largest market share, and the UK neuropathic pain market was the fastest-growing market in the European region.

The Asia-Pacific Neuropathic Pain Market is expected to grow at the fastest CAGR from 2022 to 2030. With the high frequency of the condition, Asia-Pacific has a considerable market potential for diabetic neuropathy products. For instance, research by Pan et al. indicated that individuals with type 1 and type 2 diabetes in Beijing, China, had prevalence rates of peripheral neuropathy of 21.92% and 35.34%, respectively. Moreover, China's neuropathic pain market held the largest market share, and the Indian neuropathic pain market was the fastest-growing market in the Asia-Pacific region.

Neuropathic Pain Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the neuropathic pain market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the neuropathic pain industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the neuropathic pain industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the neuropathic pain industry has provided medicine with some of the most significant benefits. The neuropathic pain market major player such as Medtronic Inc (Ireland), Abbott Laboratories (US), Stryker Corporation (US), and others are working on expanding the market demand by investing in research and development activities.

Boston Scientific Corporation is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties such as interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. In December 2021, Boston Scientific Corporation introduced the WaveWriter Alpha Spinal Cord Stimulator Systems. This medication is used to treat chronic pain and can also be used to treat neuropathic pain. This launch will increase the company's revenue and market share throughout the anticipated term.

Also, CODA Biotherapeutics is a biopharmaceutical business in the preclinical stages that is developing a chemogenetic gene therapy platform for treating intractable disorders. Its platform intends to modulate neuronal activity to treat disease. Coda Biotherapeutics Inc is working on a new chemogenetic platform for modulating neuronal activity. In May 2021, CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, announced the formation of a strategic research collaboration with the Facial Pain Research Foundation (FPRF) to identify and develop potential new therapies and cures for trigeminal neuralgia and related neuropathic pain using CODA's chemogenetic gene therapy platform.

Key Companies in the neuropathic pain market include

• Sanofi


• Abbott


• Astellas


• Pfizer


• Eli Lily


• Johnson and Johnson


• AstraZeneca


• GSK

Neuropathic Pain Industry Developments

July 2022: Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited have entered into an exclusive collaboration and commercialization agreement for NRD.E1, Novaremed's innovative non-opioid investigational drug being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.

March 2022: Daiichi Sankyo Company, Limited got approval to modify the analgesic "Tarlige Tablets" (mirogabalin besilate) indication from "peripheral neuropathic pain" to "neuropathic pain." Daiichi Sankyo presented a supplementary new drug application (sNDA) for Tarlige Tablets in May 2021 based on the findings of a phase 3 trial in patients with CNP.

Neuropathic Pain Market Segmentation

Neuropathic Pain Type Outlook

• Painful Diabetic Peripheral Neuropathy


• Autonomic Neuropathy


• Focal Neuropathy


• Proximal Neuropathy

Neuropathic Pain Indication Outlook

• Diabetic Neuropathy


• Spinal Stenosis


• Chemotherapy Induced Peripheral Neuropathy

Neuropathic Pain Diagnosis Outlook

• Imaging


• Blood Tests and Physical Examination

Neuropathic Pain Treatment Outlook

• Medications


• Multimodal Therapy

Neuropathic Pain End User Outlook

• Hospitals


• Clinics


• Research Organization

Neuropathic Pain Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America